ClinicalTrials.gg
Not yet recruitingNCT07219862Updated Oct 22, 2025

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

An interventional study of smART (Smart Antiretroviral Therapy Assistant) and Traditional Prescribing resources in HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS) and Antiretroviral Therapy, Highly Active, sponsored by Keck School of Medicine of USC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Keck School of Medicine of USC · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States — 112 open to participants now, 154 under way, 9 of them phase 3. Acquired Immunodeficiency Syndrome · United States.

Planned enrollment
275th of 1,291
250 · median 60
Started
2028
the only one that year
No phase
642 of 1,671
59 open now
Primary completion
2030-09
later than 141 of 150 live
Registered
1,644th of 1,671
by date

Among the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, this one is the 275th largest by planned enrollment of the 1,291 interventional ones that give a count, is the only one that started in 2028, is one of 642 with no phase, reaches primary completion later than 141 of the 150 other live ones, and was the 1,644th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

112 of the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging.

In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care.

The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

03

Conditions studied

  • HIV (Human Immunodeficiency Virus)
  • Clinical Decision Support System (CDSS)
  • Antiretroviral Therapy, Highly Active
  • INDIVIDUALIZED THERAPY
  • AIDS (Acquired Immune Deficiency Syndrome)
  • Personalized Medicine
  • Precision Medicine

Keywords

  • hiv
  • clinical decision support system
  • antiretroviral therapy
  • aids
  • personalized medicine
  • precision medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

patients

  1. Documented HIV-1 infection
  2. Greater than 18 years of age
  3. Genotype resistance testing previously conducted or scheduled through clinical care

Providers:

HIV care providers who will determine treatment selections, with or without utilizing our clinical decision support tool

Exclusion criteria

Exclusion Criteria:

patients:

1. Refusal or inability to give

Providers:

1. Refusal to give informed consent

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    smART

    smART (Smart Antiretroviral Therapy Assistant): a digital clinical decision support tool that provides personalized, guideline-based HIV treatment recommendations.

    Other: smART (Smart Antiretroviral Therapy Assistant)

  • Active comparator
    Traditional Prescribing resources

    standard online resources commonly accessed in HIV care, including the Stanford HIV Database, the IAS-USA Drug Resistance Mutations Chart, and the NIH HIV Clinical Guidelines.

    Other: Traditional Prescribing resources

Interventions

  • OthersmART (Smart Antiretroviral Therapy Assistant)

    smART is a single-page, offline clinical decision support application that generates personalized HIV treatment recommendations by evaluating over 50,000 possible antiretroviral combinations. The user inputs patient-specific data including genotypic resistance profile, comorbid conditions, drug allergies, concomitant medications, and reproductive status (pregnant or planning pregnancy). smART performs all computations locally and does not store any patient information, ensuring complete data privacy.

  • OtherTraditional Prescribing resources

    No additional interventions beyond standard clinical practice will be implemented for study participants. Treatment decisions will be guided by established HIV resources, including the Stanford HIV Database, the IAS-USA Drug Resistance Mutations Chart, and the NIH HIV Clinical Guidelines.

06

What researchers measure

Primary outcomes

  1. Adherence of Prescribed ART Regimens to Evidence-Based Recommendations

    Proportion of antiretroviral therapy (ART) regimens that align with guideline-based recommendations. A regimen is considered adherent if it contains at least three fully active agents (defined as a total drug susceptibility score ≥280) and is not contraindicated based on patient-specific factors identified by the smART tool, including allergies, comorbidities, concomitant medications, pregnancy status, and/or major guideline restrictions.

    Time frame: Assessed at completion of each patient prescribing session at Day 1

Secondary outcomes

  1. Proportion of virally suppressed individuals

    Viral suppression rates

    Time frame: Assessed at between 1 month and 6 month after completion of each prescribing session

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data, including drug resistance mutations, comorbidities, comedications, and prescribed regimens, will be shared by publishing manuscripts covering this trial outcomes.

Supporting information: Study protocol

Time frame: The study protocol will be published as supporting information upon completion of the trial and publication of its results.

Access criteria: Anyone with access to the academic journals publishing this study's results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2028; primary completion for Sep 2030, 24 months later.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 24 months is below that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 22, 2025
StartEst.
Sep 1, 2028
Primary completionEst.
Sep 1, 2030
CompletionEst.
Sep 1, 2031
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219862
Lead sponsor
Keck School of Medicine of USC
Collaborators
Los Angeles General Medical Center, AIDS Healthcare Foundation
Responsible party
Hayoun Lee (Associate Professor, Keck School of Medicine of USC) — Principal investigator
First posted
Oct 22, 2025
Start date
Sep 1, 2028 (estimated)
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Oct 22, 2025

Study contacts

Hayoun Lee, PhD
Contact
hayoun@usc.edu
626-318-4471
Christian Takayama, MD
Contact
ctakayama@dhs.lacounty.gov
Hayoun Lee, PhD
principal investigator · Keck School of Medicine of USC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion